Calman A. MacLennan of Novartis Vaccines Institute for Global Health in Italy will develop a technology platform for the production of highly immunogenic and affordable polysaccharide vaccines. The platform will produce bacterial polysaccharides linked to outermembrane GMMA particles, rather than to carrier proteins, that will act as adjuvants for an enhanced antibody response.
Grant ID
OPP1070067
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False